Quetiapine blocks cocaine-induced enhancement of brain stimulation reward

Behavioural Brain Research

Volumn 208, Issue 1, 2010, Pages 163-168

  Gallo, Alexandra ^a   Lapointe, Stéphanie ^a   Stip, Emmanuel ^a   Potvin, Stéphane ^a   Rompré, Pierre Paul ^a  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

Author keywords

Anhedonia; Cocaine; Dopamine; Dysphoria; Quetiapine; Reward

Indexed keywords

COCAINE; DOPAMINE; DOPAMINE RECEPTOR; QUETIAPINE; DIBENZOTHIAZEPINE DERIVATIVE; DOPAMINE UPTAKE INHIBITOR; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN DEPTH STIMULATION; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; INSTRUMENTAL CONDITIONING; LOW DRUG DOSE; MALE; MEDIAL FOREBRAIN BUNDLE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; REWARD; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL BEHAVIOR; BIOPHYSICS; DRUG EFFECT; DRUG INTERACTION; DRUG SELF ADMINISTRATION; ELECTROSTIMULATION; METHODOLOGY; PHYSIOLOGY; REINFORCEMENT; SPRAGUE DAWLEY RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BIOPHYSICS; COCAINE; CONDITIONING, OPERANT; DIBENZOTHIAZEPINES; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTRIC STIMULATION; MALE; MEDIAL FOREBRAIN BUNDLE; RATS; RATS, SPRAGUE-DAWLEY; REINFORCEMENT SCHEDULE; REWARD; SELF ADMINISTRATION;

EID: 77951936131     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.11.029     Document Type: Article

References (34)

1. Arborelius L., Chergui K., Murase S., Nomikos G.G., Hook B.B., Chouvet G., et al. The 5-HT1A receptor selective ligands (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol 1993, 347:353-362.
2. Awad A.G., Voruganti L.N. Neuroleptic dysphoria: revisiting the concept 50 years later. Acta Psychiatry Scand Suppl 2005, 427:6-13.
3. Bauco P., Wise R.A. Synergistic effects of cocaine with lateral hypothalamic brain stimulation reward: lack of tolerance or sensitization. J Pharmacol Exp Ther 1997, 283:1160-1167.
4. Benaliouad F., Kapur S., Rompré P.-P. Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward. Neuropsychopharmacology 2007, 32:551-561.
5. Broderick P.A., Kornak E.P., Eng F., Wechsler R. Real time detection of acute (IP) cocaine-enhanced dopamine and serotonin release in ventrolateral nucleus accumbens of the behaving Norway rat. Pharmacol Biochem Behav 1993, 46:715-722.
6. Cahir M., King D.J. Antipsychotics lack alpha1A/1B adrenoreceptor selectivity in the rat. Eur Neuropsychopharmacol 2005, 15:231-234.
7. de Haan L., Lavalaye J., van Bruggen M., van Nimwegen L., Booij J., van Amelsvoort T., et al. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can J Psychiatry 2004, 49:290-296.
8. De Deurwaerdere P., Spampinato U. Role of serotonin (2A) and serotonin (2B/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J Neurochem 1999, 73:1033-1042.
9. Flagstad P., Arnt J., Olsen C.K. Classical as well as novel antipsychotic drugs increase self-stimulation threshold in the rat - similar mechanism of action?. Eur J Pharmacol 2006, 544:69-76.
10. Fletcher P., Grottick A.J., Higgins G.A. Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropsychopharmacology 2002, 27:576-586.
11. Florin S.M., Kuczenski R., Segal D.S. Regional extracellular norepinephrine responses to amphetamine and cocaine and effects of clonidine pretreatment. Brain Res 1994, 654:53-62.
12. Gallistel C.R., Davis A.J. Affinity for the dopamine D2 receptor predicts neuroleptic potency in blocking the reinforcing effect of MFB stimulation. Pharmacol Biochem Behav 1983, 19:867-872.
13. Gallistel C.R., Karras D. Pimozide and amphetamine have opposing effects on the reward summation function. Pharmacol Biochem Behav 1984, 20:73-77.
14. Harrow M., Yonan C.A., Sands J.R., Marengo J. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved?. Schizophr Bull 1994, 20:327-338.
15. Hernandez G., Shizgal P. Dynamic changes in dopamine tone during self-administration of the ventral tegmental area in rats. Behav Brain Res 2009, 198:91-97.
16. Jasmin L., Narasaiah M., Tien D. Noradrenaline is necessary for the hedonic properties of addictive drugs. Vasc Pharmacol 2006, 45:243-250.
17. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003, 305:625-631.
18. Lejeune F., Millan M.J. Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535. Synapse 1998, 30:172-180.
19. McMahon L.R., Cunningham K.A. Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats. J Pharmacol Exp Ther 2001, 297:357-363.
20. Miliaressis E., Rompre P.-P., Laviolette P., Philippe L., Coulombe D. The curve-shift paradigm in self-stimulation. Physiol Behav 1986, 37:85-91.
21. Markowitz J.S., Brown C.S., Moore T.R. Atypical antipsychotics part I: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999, 33:73-85.
22. Nakajima S., Patterson R.L. The involvement of dopamine D2 receptors, but not D3 or D4 receptors, in the rewarding effect of brain stimulation in the rat. Brain Res 1997, 760:74-79.
23. Newman-Tancredi A., Gavaudan S., Conte C., Touzard M., Verriele L., Audinot V., et al. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol 1998, 355:245-256.
24. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, San Diego, CA.
25. Potvin S., Stip E., Lipp O., Elie R., Mancini-Marie A., Demers M.F., et al. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin 2006, 22:1277-1285.
26. Ranaldi R., Beninger R.J. Rostral-caudal differences in effects of nucleus accumbens amphetamine on VTA ICSS. Brain Res 1994, 642:250-251.
27. Ranaldi R., Bauco P., Wise R.A. Synergistic effects of cocaine and dizocilpine (MK-801) on brain stimulation reward. Brain Res 1997, 760:231-237.
28. Roberts D.C., Vickers G. Atypical neuroleptics increase self-administration of cocaine: evaluation of a behavioral screen for antipsychotic activity. Psychopharmacol 1984, 82:135-139.
29. Rothman R.B., Baumann M.H., Dersch C.M., Romero D.V., Rice K.C., Carroll F.I., et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001, 39:32-41.
30. Tsibulsky V.L., Grocki S., Dashevsky B.A., Kehne J.H., Schmidt C.J., Sorensen S.M., et al. D2/5-HT2A antagonism of cocaine-induced facilitation of brain stimulation reward. Pharmacol Biochem Behav 1998, 59:275-280.
31. Voruganti L., Awad A.G. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology 2004, 171:121-132.
32. Wise R.A. Addictive drugs and brain stimulation reward. Annu Rev Neurosci 1996, 19:319-340.
33. Wise R.A., Rompre P.-P. Brain dopamine and reward. Annu Rev Psychol 1989, 40:191-225.
34. Yamamura S., Ohoyama K., Hamaguchi T., Kashimoto K., Nakagawa M., Kanehara S., et al. Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex. Psychopharmacology 2009, 206:243-258.